Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide growth hormone secretagogue developed to address the receptor selectivity limitations of first-generation GHRPs. Unlike GHRP-6 or GHRP-2, ipamorelin demonstrates high selectivity for GHS-R1a with minimal cross-reactivity at ACTH, prolactin, or cortisol axes, making it a preferred tool compound in neuroendocrine research protocols where isolated GH axis stimulation is required.
GHS-R1a Receptor Binding and Signal Transduction
GHS-R1a is a seven-transmembrane Gq/11-coupled receptor expressed predominantly on pituitary somatotrophs, hypothalamic arcuate neurons, and vagal afferents. Ipamorelin binds GHS-R1a with high affinity (Ki ~1–3 nM in radioligand displacement assays), triggering intracellular calcium mobilization via phospholipase C-β activation and IP₃-mediated ER calcium release. Downstream, this converges on protein kinase C and activates cAMP-responsive elements through adenylyl cyclase sensitization. Unlike GHRP-2, ipamorelin does not significantly activate PKC-independent cortisol pathways at research concentrations (100–1000 ng/mL), which accounts for its clean endocrine profile across in vitro somatotroph preparations.
The receptor also exhibits constitutive activity (~50% of maximum in the absence of ligand), which ipamorelin further amplifies in a dose-dependent fashion. This baseline tone is relevant when interpreting GH AUC data from trough-phase sampling windows.
GH Pulse Architecture and Somatostatin Interaction
Ipamorelin produces discrete, amplitude-modulated GH pulses without disrupting the ultradian secretory rhythm set by hypothalamic GHRH/somatostatin oscillation. In rat pituitary cell preparations, 100 nM ipamorelin elevated GH release 3.2-fold above basal (p<0.001) without attenuating subsequent somatostatin-mediated inhibition — a key distinction from GHRP-6, which partially suppresses somatostatin tone. This selectivity preserves the physiological nadir between pulses, which is important for maintaining pituitary sensitivity across repeated dosing intervals.
In ovariectomized rat models, subcutaneous ipamorelin at 75 µg/kg produced peak serum GH of 87 ± 12 ng/mL versus 14 ± 3 ng/mL in vehicle controls (p<0.001), with GH AUC(0–90 min) increasing 6.1-fold. IGF-1 levels showed a secondary rise, peaking at 24–36 hours post-injection, consistent with hepatic GH receptor-mediated JAK2/STAT5b activation and downstream IGF-1 gene transcription.
Pharmacokinetic Profile
Ipamorelin has a plasma half-life of approximately 2 hours in rodent models following subcutaneous administration, with bioavailability estimated at 60–80% relative to intravenous reference. The peptide undergoes rapid proteolytic degradation by serum dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase 24.11, which cleave at the N-terminal Aib-His bond. The D-amino acid substitutions at positions 3 and 4 (D-2Nal, D-Phe) confer partial resistance to exopeptidases, extending the effective receptor exposure window compared to endogenous ghrelin.
Tissue distribution studies indicate preferential accumulation in pituitary, hypothalamus, and liver within 15–30 minutes of subcutaneous injection. At research concentrations of 100–500 ng/mL, no saturable plasma protein binding has been reported, distinguishing it from DAC-conjugated analogues.
Selectivity, IGF-1 Axis, and mTOR Signaling
GH pulse amplitude determines hepatic JAK2 phosphorylation kinetics, which in turn drives STAT5b nuclear translocation and IGF-1 transcription. Ipamorelin’s clean pulse profile — high amplitude, preserved nadir — produces IGF-1 responses that correlate linearly with GH AUC in preclinical dose-escalation studies (r²=0.87, p<0.001). Downstream, IGF-1 activates the PI3K/Akt/mTOR axis in peripheral tissues: Akt Ser473 phosphorylation increases 2.1–3.4-fold in skeletal muscle preparations exposed to IGF-1 concentrations achieved following ipamorelin-stimulated GH secretion.
ERK1/2 phosphorylation is also observed as a parallel pathway downstream of GHS-R1a activation, independent of GH secretion, suggesting direct peripheral receptor effects at tissues expressing GHS-R1a extrapituitarily. This dual mechanism is relevant when designing receptor-expression studies in adipose or cardiac tissue models.
Research Specifications and Quality Parameters
Alpha Nordisk ipamorelin is supplied as the acetate salt, confirmed by HPLC with purity >99% and molecular weight verified by LC-MS (MW 711.87 Da). Each lot is assigned a traceable code per the Alpha lot system (e.g., A26Q2IPA0541), with certificate of analysis available via alphanordisk.com/verify. Lyophilized peptide should be reconstituted in sterile bacteriostatic water and stored at −20°C; reconstituted solutions are stable for 30 days at 4°C.
For research and laboratory use only. Not for unsupervised human consumption. All data cited reflect preclinical in vitro and in vivo models; clinical translation requires independent validation under appropriate regulatory frameworks.